{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:41:50Z","timestamp":1770356510900,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gouty arthritis (GA) is a crystal-related joint disease caused by the deposition of monosodium urate (MSU) crystals, directly associated with hyperuricemia resulting from purine metabolism disorder and\/or reduced uric acid excretion. Acute attacks of typical gouty arthritis are generally relieved through the clinical use of NSAIDs, colchicine, or glucocorticoids. However, managing patients with chronic refractory gout poses challenges due to complications such as multiple tophi, gouty nephropathy, diabetes, and gastrointestinal bleeding. While there have been numerous studies on gout in recent years, research specifically regarding chronic refractory gout remains limited. The management of such cases still faces several unresolved issues, including recurrent disease flare-ups and poor patient compliance leading to inadequate drug utilization and increased risk of side effects. In this report, we present a case of successful improvement in chronic refractory gouty arthritis using the biologic agent upadacitinib sustained-release tablets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Our case report involves a 53\u2009years-old Asian patient with recurrent gouty arthritis who had a history of over 20\u2009years without regular treatment, presenting with tophi and an increasing number of painful episodes. During hospitalization, various analgesics and anti-inflammatory drugs provided inadequate relief, requiring the use of steroids to alleviate symptoms. However, tapering off steroids proved challenging. We decided to add upadacitinib sustained-release tablets to the treatment regimen, which ultimately improved the patient\u2019s condition. After 6\u2009months of follow-up, the patient has not experienced any further acute pain episodes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the potential therapeutic effect of upadacitinib sustained-release tablets during the acute phase of chronic refractory gouty arthritis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1357117","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T04:54:28Z","timestamp":1711601668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review"],"prefix":"10.3389","volume":"11","author":[{"given":"Lishi","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.NPR.0000696896.83494.fe","article-title":"An update on gout diagnosis and management for the primary care provider","volume":"45","author":"Mbuyi","year":"2020","journal-title":"Nurse Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2310\/7750.2007.00002","article-title":"Miliarial gout (a new entity)","volume":"11","author":"Shukla","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/j.1875-9114.1991.tb02629.x","article-title":"Colchicine: a state-of-the-art review","volume":"11","author":"Levy","year":"1991","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3109\/15563650.2010.509101","article-title":"Multiple organ failure after an overdose of less than 0.4 mg\/kg of colchicine: role of coingestants and drugs during intensive care management","volume":"48","author":"Montiel","year":"2010","journal-title":"Clin Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e241977","DOI":"10.1136\/bcr-2021-241977","article-title":"Colchicine-induced rhabdomyolysis: a review of 83 cases","volume":"14","author":"Abudalou","year":"2021","journal-title":"BMJ Case Rep"},{"key":"ref6","first-page":"458","article-title":"Superior digestive tract side effects after prolonged treatment with NSAIDs in patients with osteoarthritis","volume":"8","author":"Rogoveanu","year":"2015","journal-title":"J Med Life"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40266-019-00661-0","article-title":"Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis","volume":"36","author":"Honvo","year":"2019","journal-title":"Drugs Aging"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/ard.2003.015743","article-title":"Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option","volume":"63","author":"Tausche","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2050313X1351977","DOI":"10.1177\/2050313X13519774","article-title":"Tocilizumab improved clinical symptoms of a patient with systemic tophaceous gout who had symmetric polyarthritis and fever: an alternative treatment by blockade of interleukin-6 signaling","volume":"2","author":"Mokuda","year":"2014","journal-title":"SAGE Open Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.reuma.2012.06.009","article-title":"Tocilizumab in a patient with tophaceous gout resistant to treatment","volume":"9","author":"Pinto","year":"2013","journal-title":"Reumatol Clin"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ph15010030","article-title":"Molecular modeling insights into upadacitinib selectivity upon binding to JAK protein family","volume":"15","author":"Taldaev","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","article-title":"Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis","volume":"55","author":"Mohamed","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","article-title":"A review of upadacitinib in rheumatoid arthritis","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-roth","year":"2020","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"Mcinnes","year":"2021","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/JIR.S357159","article-title":"Combination of uric acid and pro-inflammatory cytokines in discriminating patients with gout from healthy controls","volume":"15","author":"Zha","year":"2022","journal-title":"J Inflamm Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI94584","article-title":"Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation","volume":"128","author":"Hall","year":"2018","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.12.28","article-title":"Therapeutic effects of upadacitinib on experimental autoimmune uveitis: insights from single-cell analysis","volume":"64","author":"Huang","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/ar3508","article-title":"T cells as key players for bone destruction in gouty arthritis?","volume":"13","author":"Harre","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"672461","DOI":"10.3389\/fimmu.2021.672461","article-title":"Targeting JAK-STAT signalling alters PsA synovial fibroblast pro-inflammatory and metabolic function","volume":"12","author":"O\u2019Brien","year":"2021","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"00049","DOI":"10.1016\/j.jaad.2024.01.004","article-title":"Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study","volume":"24","author":"Avallone","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/ced.15104","article-title":"Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib","volume":"47","author":"Ferrucci","year":"2022","journal-title":"Clin Exp Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1357117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T04:54:54Z","timestamp":1711601694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1357117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":33,"alternative-id":["10.3389\/fmed.2024.1357117"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1357117","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"article-number":"1357117"}}